Moderna's COVID-19 vaccine has shown to be 100 percent effective in adolescents aged 12 to 17, the pharmaceutical company announced Tuesday. Plans are underway to submit these findings to global regulators within days.
"We are encouraged that mRNA-1273 was highly effective at preventing COVID-19 in adolescents. It is particularly exciting to see that the Modern COVID-19 vaccine can prevent SARS-CoV-2 infection," Moderna CEO Stephane Bancel stated. "We will submit these results to the U.S. [Food and Drug Administration (FDA)] and regulators globally in early June and request authorization. We remain committed to doing our part to help end the COVID-19 pandemic."
3,732 participants aged 12 to 17 took part in Moderna's studies. Zero cases of COVID-19 were found among vaccinated participants. The vaccine was reportedly 93 percent effective two weeks after the first dose and 100 percent effective after the second dose of Moderna's vaccine.
News of Moderna's success among adolescence comes just weeks after Pfizer's vaccine was authorized for children aged 12 to 15. Meanwhile, new CDC guidance has allowed fully inoculated individuals to return to some sense of normalcy, while still remaining cautious. Some city's students are also expected to return to a fully in-person format in the Fall, which would provide much-needed time for students to get vaccinated before their classes resume.